Cellular dormancy in minimal residual disease following targeted therapy

BACKGROUND: Breast cancer mortality is principally due to tumor recurrence, which can occur following extended periods of clinical remission that may last decades. While clinical latency has been postulated to reflect the ability of residual tumor cells to persist in a dormant state, this hypothesis...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Breast Cancer Res
Auteurs principaux: Ruth, Jason R., Pant, Dhruv K., Pan, Tien-chi, Seidel, Hans E., Baksh, Sanjeethan C., Keister, Blaine A., Singh, Rita, Sterner, Christopher J., Bakewell, Suzanne J., Moody, Susan E., Belka, George K., Chodosh, Lewis A.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2021
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8178846/
https://ncbi.nlm.nih.gov/pubmed/34088357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-021-01416-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires